Bioluminescence-based high-throughput screening and identification of direct-acting dengue virus NS5 methyltransferase inhibitors.

Authors

Chenchen Li, Jianfang Zhang, Yuegao Hu, Yanyang Su, Ni Liu, Zhang Zhang, Qinhai Ma, Zifeng Yang, Yingjun Li

Published in

International journal of biological macromolecules. Pages 154293. Sep 04, 2026. Epub Sep 04, 2026.

Abstract

Dengue virus (DENV) is a mosquito-borne orthoflavivirus that infects millions of people annually across tropical and subtropical regions, posing a severe and growing threat to global public health. Currently there are no antiviral drugs available for DENV infection. The methyltransferase domain of non-structural protein 5 (NS5 MTase) catalyzes two essential methylation reaction in synthesis of the 5' cap-1 structure of viral mRNA, making it a promising yet under-validated target for anti-DENV drug development. Herein, we optimized a bioluminescence-based enzymatic MTase-Glo assay using purified recombinant DENV NS5 MTase and performed high-throughput screening of the focused Methylation Compound Library. Four compounds-SGC0946, AMI-1, salirasib, and gambogenic acid-were identified as potent DENV methylation inhibitors effective against all four serotypes (DENV-1 to -4). Surface plasmon resonance (SPR) analysis confirmed the direct binding between inhibitors and NS5 MTase. Among them, SGC0946 exhibited the strongest inhibitory activity with a half-maximal inhibitory concentration (IC₅₀) of 0.05-0.11 μM against DENV-1 to -4. Molecular docking predicted that SGC0946 binds to the S-adenosylmethionine (SAM)-binding pocket of NS5 MTase. In addition, SGC0946 suppressed DENV replication in C6/36 and BHK-21 cells with EC50 values of 6.67 and 0.60 μM, respectively. Collectively, these findings identify novel DENV MTase inhibitors with diverse scaffolds and provide valuable molecular insights for the rational design of more potent NS5 MTase-targeting inhibitors in the future.

PMID:
42697293
Bibliographic data and abstract were imported from PubMed on 05 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.